GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
about
Brain delivery of proteins via their fatty acid and block copolymer modificationsAgile delivery of protein therapeutics to CNSGLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Integration of satiety signals by the central nervous system.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Cardiovascular safety and benefits of GLP-1 receptor agonists.Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
P2860
Q30354932-E581C9BB-836C-46E3-9D6B-7C27CEF2D71BQ34079647-63C2A24F-14AE-4E50-8FD5-373F571DB309Q36406821-BEED33A5-BEAC-4D3F-AA6A-3319517E5E56Q36803151-C15C05CA-1984-4F33-A6A3-9D564C379F35Q38105423-B131BABC-9C46-401D-A23C-048BF751C346Q38199526-B7CDA9E3-8587-474F-A508-A5C8D777E8E2Q38235219-F153BD1F-D0E8-48E6-AB4E-BF32A8F7E9BDQ38236774-099C3404-F603-4B7E-907D-72D0909091B2Q38286444-B942915B-29E1-4EA2-AB60-B64869AEBEBCQ38606170-36E43540-ECCC-4E11-B0BC-7101B6942ED2Q39013056-8513EB30-9781-4AA6-B90C-291822ED5E96Q39204459-AAD7AA2D-3F3E-495A-8D47-FA5A1BDDEF6CQ42648850-CCF0645D-0828-457F-BBDB-A05435A3D8D2
P2860
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
@en
type
label
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
@en
prefLabel
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
@en
P2860
P1476
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
@en
P2093
Maria J Jespersen
P2860
P356
10.1517/17425255.2013.731394
P407
P577
2012-10-24T00:00:00Z